Unused COVID-19 Pills and Antibody Supplies Increase

The U.S. federal government replenishes COVID-19 therapeutic inventories each Monday. The current information from the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) indicates there is plenty of oral antivirals and monoclonal antibody (mAbs) supply available in the USA.

As of May 17, 2022, ASPR's COVID-19 Therapeutics Summary revealed:

• Paxlovid: Ordered = 2,056,968, Administrered = 668,954

• Lagevrio: Ordered = 1,799,949, Administrered = 230,257

• Bebtelovimab: Ordered = 347,291, Administrered = 76,103

• Evusheld: Ordered = 681,793, Administrered = 253,454

The U.S. FDA authorized COVID-19 oral antivirals Paxlovid and Lagevrio threshold amounts are determined on a pro-rata population basis.

And the mAbs treatment Bebtelovimab threshold amounts are determined using a disease-based methodology.

While the mAbs Evusheld threshold amounts are determined on a pro-rata population basis, and replenishment occurs monthly.

Furthermore, threshold quantities are determined by ASPR using the same methodology as previous allocations. 

Each state and territorial health department can make product requests at any time if a jurisdiction's current supply is not sufficient to meet demand.

Note: This ASPR information was curated for mobile readership.